UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

Clinical cancer research, 2017-08, Vol.23 (15), p.3994-4003

2017

Volltextzugriff (PDF)

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

Critical care (London, England), 2020-05, Vol.24 (1), p.241-241, Article 241

2020

Volltextzugriff (PDF)

M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect

Statistics in medicine, 2022-02, Vol.41 (4), p.815-830

2022

Volltextzugriff (PDF)

Dynamic prediction of disease processes based on recurrent history and functional principal component analysis of longitudinal biomarkers: Application for ovarian epithelial cancer

Statistics in medicine, 2021-04, Vol.40 (8), p.2006-2023

2021

Volltextzugriff (PDF)

Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome

Neoplasia (New York, N.Y.), 2019-06, Vol.21 (6), p.591-601

2019

Volltextzugriff (PDF)

A comparative study of adaptive trial designs for dose optimization

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2023-09, Vol.22 (5), p.797-814

2023

Volltextzugriff (PDF)

Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krüppel‐like factors in prostate cancer

Journal of cellular and molecular medicine, 2020-05, Vol.24 (10), p.5797-5810

2020

Volltextzugriff (PDF)

Single-Cell Transcriptomics Reveals Cellular Heterogeneity and Drivers in Serrated Pathway-Driven Colorectal Cancer Progression

International journal of molecular sciences, 2024-10, Vol.25 (20), p.10944

2024

Volltextzugriff (PDF)

IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy

BMC medical research methodology, 2023-03, Vol.23 (1), p.66-66, Article 66

2023

Volltextzugriff (PDF)

Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses

Clinical trials (London, England), 2024-06, Vol.21 (3), p.308-321

2024

Volltextzugriff (PDF)

Local continual reassessment methods for dose finding and optimization in drug-combination trials

Statistical methods in medical research, 2023-10, Vol.32 (10), p.2049-2063

2023

Volltextzugriff (PDF)

PIPET: predicting relevant subpopulations in single-cell data using phenotypic information from bulk data

Briefings in bioinformatics, 2024-05, Vol.25 (4)

2024

Volltextzugriff (PDF)

Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors

Journal of biopharmaceutical statistics, 2022-01, Vol.32 (1), p.34-52

2022

Volltextzugriff (PDF)

A three-dimensional electrochemical oxidation system with α-Fe2O3/PAC as the particle electrode for ammonium nitrogen wastewater treatment

RSC advances, 2020-02, Vol.10 (15), p.8773-8779

2020

Volltextzugriff (PDF)

A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination

Journal of biopharmaceutical statistics, 2024-07, Vol.34 (4), p.582-595

2024

Volltextzugriff (PDF)

Shotgun-2: A Bayesian phase I/II basket trial design to identify indication-specific optimal biological doses

Statistical methods in medical research, 2023-03, Vol.32 (3), p.443-464

2023

Volltextzugriff (PDF)

Functional principal components analysis on moving time windows of longitudinal data: dynamic prediction of times to event

Journal of the Royal Statistical Society Series C: Applied Statistics, 2018-08, Vol.67 (4), p.961-978

2018

Volltextzugriff (PDF)

Integrative analysis identifies region- and sex-specific gene networks and Mef2c as a mediator of anxiety-like behavior

Cell reports (Cambridge), 2024-07, Vol.43 (7), p.114455, Article 114455

2024

Volltextzugriff (PDF)

Dynamic prognostic model for kidney renal clear cell carcinoma (KIRC) patients by combining clinical and genetic information

Scientific reports, 2018-12, Vol.8 (1), p.17613-7, Article 17613

2018

Volltextzugriff (PDF)

One-Year Outcomes after PCI Strategies in Cardiogenic Shock

The New England journal of medicine, 2019-05, Vol.380 (19), p.1876-1877

2019

Volltextzugriff (PDF)

Multiomics data reveals the influences of myasthenia gravis on thymoma and its precision treatment

Journal of cellular physiology, 2021-02, Vol.236 (2), p.1214-1227

2021

Volltextzugriff (PDF)

Bayesian two‐stage sequential enrichment design for biomarker‐guided phase II trials for anticancer therapies

Biometrical journal, 2022-10, Vol.64 (7), p.1192-1206

2022

Volltextzugriff (PDF)

Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2024-01, Vol.23 (1), p.107-133

2024

Volltextzugriff (PDF)

A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect

Statistical methods in medical research, 2021-03, Vol.30 (3), p.904-915

2021

Volltextzugriff (PDF)

BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials

Clinical trials (London, England), 2023-10, Vol.20 (5), p.486-496

2023

Volltextzugriff (PDF)

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(172)
Mit Volltextzugriff
(191)

Publikationsform

Sprache

Englisch
(203)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

Adjuvant corticosteroid therapy for critically ill patients with COVID-19

M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect

Dynamic prediction of disease processes based on recurrent history and functional principal component analysis of longitudinal biomarkers: Application for ovarian epithelial cancer

Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome

A comparative study of adaptive trial designs for dose optimization

Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krüppel‐like factors in prostate cancer

Single-Cell Transcriptomics Reveals Cellular Heterogeneity and Drivers in Serrated Pathway-Driven Colorectal Cancer Progression

IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy

Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses

Local continual reassessment methods for dose finding and optimization in drug-combination trials

PIPET: predicting relevant subpopulations in single-cell data using phenotypic information from bulk data

Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors

A three-dimensional electrochemical oxidation system with α-Fe2O3/PAC as the particle electrode for ammonium nitrogen wastewater treatment

A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination

Shotgun-2: A Bayesian phase I/II basket trial design to identify indication-specific optimal biological doses

Functional principal components analysis on moving time windows of longitudinal data: dynamic prediction of times to event

Integrative analysis identifies region- and sex-specific gene networks and Mef2c as a mediator of anxiety-like behavior

Dynamic prognostic model for kidney renal clear cell carcinoma (KIRC) patients by combining clinical and genetic information

One-Year Outcomes after PCI Strategies in Cardiogenic Shock

Multiomics data reveals the influences of myasthenia gravis on thymoma and its precision treatment

Bayesian two‐stage sequential enrichment design for biomarker‐guided phase II trials for anticancer therapies

Group sequential design with maximin efficiency robust test for immunotherapy with generalized delayed treatment effect

A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect

BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials

Suchergebnisse filtern